Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Immunome, Inc. (IMNM)
USD22.88
+0.08 (+0.37%)
US NASDAQ Healthcare Biotechnology
Address
18702 North Creek Parkway 98011
Bothell, WA, US
Bothell, WA, US
CEO
Clay Siegall
Website
immunome.com
IPO
2020-10-02
CIK 1472012 ISIN US45257U1088
Description
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
News Sentiment (7d)
3 articles
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Date | Filing |
|---|---|---|
| Morphimmune Inc. | 2023-08-08 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD22.88
+0.08 (+0.37%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
2.07
Float Shares
72.83M
Free Float %
82.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.16% | +0.05% | -1.86% | +0.18% | +34.46% | +3.35% | +180.66% | +256.91% | +35.95% | +65.06% | +65.06% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
22.88
Low
32.00
+39.8%
Consensus
36.83
+60.9%
Median
38.00
+66.0%
High
40.00
+74.8%
DCF (Unlevered)
7.38
-67.8%
DCF (Levered)
7.26
-68.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 11 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
40.00
+74.8%
|
| Last Year | 8 |
33.13
+44.8%
|
| All Time | 11 |
32.36
+41.4%
|
Quality scores
Altman Z-Score
36.59
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-23.2% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+51.4% ★ Q1'26: +7.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-3,304.1%
-
EBIT margin Biotechnology: +0.0%-3,084.8%
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+49.0% Q1'26: +42.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 11 EPS Ana. |
Dec 2027 9 Rev. Ana. 9 EPS Ana. |
Dec 2028 9 Rev. Ana. 8 EPS Ana. |
Dec 2029 4 Rev. Ana. 6 EPS Ana. |
Dec 2030 4 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 2.10M (-100.0%)
|
14.02M
est: 10.78M (+30.0%)
|
9.04M
est: 9.41M (-3.9%)
|
6.94M
est: 7.72M (-10.0%)
|
4.44M
2.05M – 6.82M
-42.5% YoY
|
74.88M
11.66M – 153.94M
+1,587.0% YoY
|
239.90M
58.49M – 457.50M
+220.4% YoY
|
400.66M
97.69M – 764.08M
+67.0% YoY
|
619.72M
151.10M – 1.18B
+54.7% YoY
|
| EBITDA |
-17.04M
est: 420.0K (-4,157.9%)
|
-28.00M
est: -2.16M (-1,198.2%)
|
-151.35M
est: -1.88M (-7,945.2%)
|
-211.16M
est: -1.54M (-13,583.7%)
|
-887.7K
-1.36M – -410.5K
+42.5% YoY
|
-14.98M
-30.79M – -2.33M
-1,587.0% YoY
|
-47.98M
-91.50M – -11.70M
-220.4% YoY
|
-80.13M
-152.82M – -19.54M
-67.0% YoY
|
-123.94M
-236.37M – -30.22M
-54.7% YoY
|
| EBIT |
-17.80M
est: 420.0K (-4,337.6%)
|
-28.73M
est: -2.16M (-1,232.0%)
|
-153.46M
est: -1.88M (-8,057.0%)
|
-214.11M
est: -1.54M (-13,775.2%)
|
-887.7K
-1.36M – -410.5K
+42.5% YoY
|
-14.98M
-30.79M – -2.33M
-1,587.0% YoY
|
-47.98M
-91.50M – -11.70M
-220.4% YoY
|
-80.13M
-152.82M – -19.54M
-67.0% YoY
|
-123.94M
-236.37M – -30.22M
-54.7% YoY
|
| Net Income |
-17.84M
est: -506.06M (+96.5%)
|
-106.81M
est: -262.59M (+59.3%)
|
-292.96M
est: -384.51M (+23.8%)
|
-212.39M
est: -194.32M (-9.3%)
|
-198.93M
-229.53M – -168.32M
-2.4% YoY
|
-185.97M
-234.82M – -137.11M
+6.5% YoY
|
-143.05M
-231.78M – -38.76M
+23.1% YoY
|
-3.38M
-7.38M – -57.4K
+97.6% YoY
|
116.72M
1.98M – 254.36M
+3,548.4% YoY
|
| SGA |
4.78M
est: 3.38M (+41.3%)
|
19.66M
est: 28.80M (-31.7%)
|
32.96M
est: 25.12M (+31.2%)
|
43.77M
est: 20.61M (+112.4%)
|
11.85M
5.48M – 18.23M
-42.5% YoY
|
199.97M
31.15M – 411.11M
+1,587.0% YoY
|
640.68M
156.21M – 1.22B
+220.4% YoY
|
1.07B
260.89M – 2.04B
+67.0% YoY
|
1.66B
403.52M – 3.16B
+54.7% YoY
|
| EPS |
-1.69
est: -8.63 (+80.4%)
|
-5.38
est: -6.31 (+14.7%)
|
-5.00
est: -4.38 (-14.1%)
|
-2.43
est: -2.24 (-8.3%)
|
-2.31
-2.63 – -1.93
-2.7% YoY
|
-2.12
-2.69 – -1.57
+7.8% YoY
|
-1.09
-2.65 – -0.44
+48.5% YoY
|
-0.04
-0.08 – 0.00
+96.5% YoY
|
1.34
0.02 – 2.91
+3,548.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-203.46M
OE per share TTM
-2.39
Owner's Yield
-10.13%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
136.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
47
Total invested
104.41M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 85-4328500 | 5.76M | 9.60% | 5.76M | — | 5.76M | — | IA | Maryland | 2024-11-14 | ↗ |
| 2 | (1) BlackRock, Inc. | 3.98M | 6.60% | — | — | — | — | HC | Delaware | 2024-10-22 | ↗ |
| 3 | Abigail P. Johnson | 3.91M | 9.14% | — | — | 3.91M | — | IN | Delaware | 2024-02-09 | ↗ |
| 4 | FMR LLC | 3.91M | 9.14% | 3.91M | — | 3.91M | — | HC | Delaware | 2024-02-09 | ↗ |
| 5 | EcoR1 Capital, LLC | 3.88M | 11.00% | — | 3.88M | — | — | IA, OO | Delaware | 2023-10-12 | ↗ |
| 6 | Oleg Nodelman | 3.88M | 11.00% | — | 3.88M | — | — | HC, IN | Delaware | 2023-10-12 | ↗ |
| 7 | Jeremy C. Green | 3.88M | 9.10% | — | 3.88M | — | 3.88M | HC, IN | Delaware | 2023-10-12 | ↗ |
| 8 | Redmile Biopharma Investments III, L.P. | 3.88M | 9.10% | — | 3.88M | — | 3.88M | PN | Delaware | 2023-10-12 | ↗ |
| 9 | Redmile Group, LLC | 3.88M | 9.10% | — | 3.88M | — | 3.88M | IA, OO | Delaware | 2023-10-12 | ↗ |
| 10 | EcoR1 Capital Fund Qualified, L.P. | 3.66M | 11.00% | — | 3.66M | — | 3.66M | PN | Delaware | 2023-10-12 | ↗ |
| 11 | EIN #00-0000000 | 3.49M | 5.80% | — | 3.49M | — | 3.49M | IA, HC | Jersey, Channel Islands | 2024-11-14 | ↗ |
| 12 | Isaac Barchas | 2.91M | 6.80% | 198.6K | 2.71M | 198.6K | 2.71M | IN | — | 2023-10-12 | ↗ |
| 13 | Morphimmune Inc. | 2.66M | 20.00% | — | 2.66M | — | — | CO | — | 2023-07-07 | ↗ |
| 14 | Arsenal Bridge Advisors, LLC | 2.41M | 5.60% | — | 2.41M | — | 2.41M | OO | — | 2023-10-12 | ↗ |
| 15 | James Graham | 2.41M | 5.60% | — | 2.41M | — | 2.41M | IN | — | 2023-10-12 | ↗ |
| 16 | Arsenal Bridge Venture II, LLC | 1.47M | 3.40% | — | 1.47M | — | 1.47M | OO | — | 2023-10-12 | ↗ |
| 17 | Michael Rapoport | 1.18M | 9.60% | 1.18M | — | 1.18M | — | IN | United States of America | 2022-02-14 | ↗ |
| 18 | Arsenal Bridge Venture II-B, LLC | 942.8K | 2.20% | — | 942.8K | — | 942.8K | OO | — | 2023-10-12 | ↗ |
| 19 | Michael Zimmerman | 920.1K | 7.60% | — | 920.1K | — | 920.1K | IN | Citizenship or Place of Organization: | 2022-02-14 | ↗ |
| 20 | Prentice Capital Management, LP | 920.1K | 7.60% | — | 920.1K | — | 920.1K | PN | Delaware | 2022-02-14 | ↗ |
| 21 | Alpine Global Management, LLC | 862.2K | 7.10% | 862.2K | — | 862.2K | — | OO | Delaware, USA | 2022-01-14 | ↗ |
| 22 | Family Office, LLC | 660.5K | 5.59% | — | 660.5K | — | 660.5K | OO | Delaware | 2021-08-23 | ↗ |
| 23 | Philip Wagenheim | 403.7K | 3.30% | — | — | 403.7K | — | IN | or Place of Organization | 2022-02-14 | ↗ |
| 24 | I. Wistar Morris III | 386.1K | 3.20% | 386.1K | — | 386.1K | — | IN | Citizenship or Place of Organization | 2022-02-14 | ↗ |
| 25 | Research Bridge Partners, Inc. | 297.9K | 0.70% | — | 297.9K | — | 297.9K | CO | — | 2023-10-12 | ↗ |
| 26 | RBP Catalyst Fund, L.P. | 176.3K | 0.40% | — | 176.3K | — | 176.3K | PN | — | 2023-10-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
47
-147 vs prev Q
New positions
9
Closed positions
145
Increased
24
Reduced
10
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 82.6K +82.6K (+100.0%) | 1.77B +1.8B (+100.0%) | 0.09% +0.094 pp | 0.00% +0.003 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 16.55M +3.5M (+26.8%) | 355.49M +202.6M (+132.5%) | 18.82% +3.810 pp | 0.02% +0.010 pp | USD13.58 +58.2% | 9 qtrs — |
| 3 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 13.42M +5.0M (+59.4%) | 288.31M +189.7M (+192.5%) | 15.26% +5.585 pp | 0.18% +0.122 pp | USD16.05 +33.8% | 8 qtrs — |
| 4 | BLACKROCK, INC. | 7.59M +1.8M (+30.4%) | 163.14M +95.0M (+139.3%) | 8.63% +1.943 pp | 0.00% +0.002 pp | USD14.45 +48.7% | 6 qtrs — |
| 5 | POINT72 ASSET MANAGEMENT, L.P. | 7.03M +2.2M (+45.8%) | 151.11M +94.6M (+167.5%) | 8.00% +2.453 pp | 0.17% +0.074 pp | USD12.33 +74.2% | 11 qtrs — |
| 6 | VANGUARD GROUP INC | 6.04M +1.1M (+23.4%) | 129.71M +72.4M (+126.3%) | 6.87% +1.241 pp | 0.00% +0.001 pp | USD13.60 +57.9% | 20 qtrs — |
| 7 | REDMILE GROUP, LLC | 5.72M +695.0K (+13.8%) | 122.83M +64.0M (+108.8%) | 6.50% +0.728 pp | 9.05% +3.322 pp | USD13.51 +59.0% | 9 qtrs — |
| 8 | ENAVATE SCIENCES GP, LLC | 4.77M +— (+0.0%) | 102.43M +46.6M (+83.4%) | 5.42% -0.059 pp | 20.21% +3.163 pp | USD9.57 +124.5% | 5 qtrs — |
| 9 | PRIMECAP MANAGEMENT CO/CA/ | 4.69M +1.7M (+55.2%) | 100.64M +65.3M (+184.8%) | 5.33% +1.858 pp | 0.08% +0.049 pp | USD12.67 +69.5% | 8 qtrs — |
| 10 | STATE STREET CORP | 3.87M +1.1M (+37.9%) | 83.08M +50.3M (+153.0%) | 4.40% +1.175 pp | 0.00% +0.002 pp | USD14.43 +48.9% | 20 qtrs — |
| 11 | DRIEHAUS CAPITAL MANAGEMENT LLC | 3.71M +3.0M (+432.0%) | 79.60M +71.4M (+875.9%) | 4.21% +3.413 pp | 0.54% +0.482 pp | USD19.35 +11.0% | 4 qtrs — |
| 12 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.38M -362.5K (-9.7%) | 72.61M +28.8M (+65.7%) | 3.84% -0.459 pp | 0.01% +0.003 pp | USD13.19 +62.9% | 10 qtrs — |
| 13 | JPMORGAN CHASE & CO | 2.86M +2.8M (+8,659.2%) | 61.34M +61.0M (+15,967.2%) | 3.25% +3.209 pp | 0.00% +0.004 pp | USD21.36 +0.6% | 11 qtrs — |
| 14 | ECOR1 CAPITAL, LLC | 2.86M -1.2M (-30.0%) | 61.34M +13.6M (+28.4%) | 3.25% -1.442 pp | 2.78% +0.491 pp | USD10.51 +104.4% | 9 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 2.36M +466.8K (+24.6%) | 50.73M +28.5M (+128.6%) | 2.68% +0.507 pp | 0.00% +0.002 pp | USD13.46 +59.6% | 21 qtrs — |
| 16 | JEFFERIES FINANCIAL GROUP INC. | 2.00M -100.0K (-4.8%) | 42.96M +18.4M (+74.7%) | 2.27% -0.140 pp | 0.22% +0.103 pp | USD13.40 +60.3% | 8 qtrs — |
| 17 | READYSTATE ASSET MANAGEMENT LP | 1.84M +524.9K (+39.8%) | 39.59M +24.2M (+156.5%) | 2.10% +0.581 pp | 1.61% +0.947 pp | USD12.46 +72.4% | 4 qtrs — |
| 18 | CITADEL ADVISORS LLC | 1.74M +899.6K (+106.9%) | 37.39M +27.5M (+279.6%) | 1.98% +1.012 pp | 0.01% +0.004 pp | USD16.76 +28.2% | 12 qtrs — |
| 19 | MORGAN STANLEY | 1.71M -124.7K (-6.8%) | 36.71M +15.2M (+71.0%) | 1.94% -0.165 pp | 0.00% +0.001 pp | USD11.40 +88.4% | 21 qtrs — |
| 20 | SOFINNOVA INVESTMENTS, INC. | 1.62M +1.2M (+271.2%) | 34.76M +29.7M (+580.8%) | 1.84% +1.339 pp | 1.50% +1.220 pp | USD20.89 +2.8% | 8 qtrs — |
| 21 | WOODLINE PARTNERS LP | 1.58M +300.7K (+23.6%) | 33.84M +18.9M (+126.7%) | 1.79% +0.326 pp | 0.13% +0.061 pp | USD12.99 +65.4% | 9 qtrs — |
| 22 | BALYASNY ASSET MANAGEMENT L.P. | 1.43M +1.4M (+100.0%) | 30.71M +30.7M (+100.0%) | 1.63% +1.625 pp | 0.04% +0.039 pp | USD21.48 +0.0% | 3 qtrs — |
| 23 | PRINCIPAL FINANCIAL GROUP INC | 1.40M +299.5K (+27.1%) | 30.17M +17.2M (+133.2%) | 1.60% +0.327 pp | 0.02% +0.009 pp | USD13.21 +62.6% | 3 qtrs — |
| 24 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.13M +1.1M (+100.0%) | 24.19M +24.2M (+100.0%) | 1.28% +1.280 pp | 3.36% +3.360 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 25 | WELLINGTON MANAGEMENT GROUP LLP | 934.5K +680.4K (+267.8%) | 20.07M +17.1M (+574.7%) | 1.06% +0.770 pp | 0.00% +0.003 pp | USD19.49 +10.2% | 8 qtrs — |
| 26 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 840.7K +177.1K (+26.7%) | 18.06M +10.3M (+132.4%) | 0.96% +0.193 pp | 0.00% +0.002 pp | USD14.09 +52.4% | 8 qtrs — |
| 27 | JANUS HENDERSON GROUP PLC | 832.1K +68.9K (+9.0%) | 17.87M +8.9M (+100.0%) | 0.95% +0.069 pp | 0.01% +0.004 pp | USD13.01 +65.1% | 9 qtrs — |
| 28 | NORTHERN TRUST CORP | 828.7K +122.2K (+17.3%) | 17.80M +9.5M (+115.2%) | 0.94% +0.130 pp | 0.00% +0.001 pp | USD13.67 +57.1% | 21 qtrs — |
| 29 | POLAR CAPITAL HOLDINGS PLC | 793.4K -265.4K (-25.1%) | 17.04M +4.6M (+37.5%) | 0.90% -0.315 pp | 0.07% +0.006 pp | USD9.43 +127.8% | 3 qtrs — |
| 30 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 779.6K +779.6K (+100.0%) | 16.75M +16.7M (+100.0%) | 0.89% +0.886 pp | 0.13% +0.131 pp | USD21.48 +0.0% | 4 qtrs — |
| 31 | TD ASSET MANAGEMENT INC | 759.2K +57.9K (+8.3%) | 16.31M +8.1M (+98.6%) | 0.86% +0.057 pp | 0.01% +0.007 pp | USD13.11 +63.8% | 10 qtrs — |
| 32 | GOLDMAN SACHS GROUP INC | 752.7K +543.8K (+260.2%) | 16.17M +13.7M (+560.8%) | 0.86% +0.616 pp | 0.00% +0.002 pp | USD18.97 +13.2% | 8 qtrs — |
| 33 | MARSHALL WACE, LLP | 737.1K +44.9K (+6.5%) | 15.83M +7.7M (+95.3%) | 0.84% +0.043 pp | 0.01% +0.006 pp | USD13.65 +57.4% | 8 qtrs — |
| 34 | PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 732.5K +230.0K (+45.8%) | 15.73M +9.8M (+167.4%) | 0.83% +0.255 pp | 6.08% +2.681 pp | USD14.78 +45.3% | 2 qtrs — |
| 35 | NAN FUNG TRINITY (HK) LTD | 714.6K +122.5K (+20.7%) | 15.35M +8.4M (+121.4%) | 0.81% +0.132 pp | 1.22% +0.524 pp | USD11.53 +86.3% | 3 qtrs — |
| 36 | CANDRIAM S.C.A. | 539.9K -319.6K (-37.2%) | 11.60M +1.5M (+15.2%) | 0.61% -0.374 pp | 0.06% +0.005 pp | USD10.82 +98.5% | 3 qtrs — |
| 37 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 435.1K +8.9K (+2.1%) | 9.35M +4.4M (+87.3%) | 0.49% +0.005 pp | 0.40% +0.196 pp | USD10.05 +113.7% | 5 qtrs — |
| 38 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 432.7K +236.9K (+121.0%) | 9.29M +7.0M (+305.4%) | 0.49% +0.267 pp | 0.00% +0.001 pp | USD16.96 +26.7% | 11 qtrs — |
| 39 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 347.7K +347.7K (+100.0%) | 7.47M +7.5M (+100.0%) | 0.40% +0.395 pp | 0.38% +0.383 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 40 | ATIKA CAPITAL MANAGEMENT LLC | 334.3K +334.3K (+100.0%) | 7.18M +7.2M (+100.0%) | 0.38% +0.380 pp | 0.76% +0.756 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 41 | DIMENSIONAL FUND ADVISORS LP | 316.4K -22.0K (-6.5%) | 6.80M +2.8M (+71.5%) | 0.36% -0.029 pp | 0.00% +0.001 pp | USD10.96 +96.0% | 3 qtrs — |
| 42 | UBS GROUP AG | 307.2K -276.7K (-47.4%) | 6.60M -239.4K (-3.5%) | 0.35% -0.322 pp | 0.00% +0.000 pp | USD10.33 +107.9% | 21 qtrs — |
| 43 | ALYESKA INVESTMENT GROUP, L.P. | 293.8K +293.8K (+100.0%) | 6.31M +6.3M (+100.0%) | 0.33% +0.334 pp | 0.02% +0.018 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 44 | KENNEDY CAPITAL MANAGEMENT LLC | 286.4K +28.9K (+11.2%) | 6.15M +3.1M (+104.0%) | 0.33% +0.030 pp | 0.13% +0.064 pp | USD11.84 +81.4% | 5 qtrs — |
| 45 | PARKMAN HEALTHCARE PARTNERS LLC | 277.8K -73.3K (-20.9%) | 5.97M +1.9M (+45.1%) | 0.32% -0.088 pp | 0.57% +0.139 pp | USD11.71 +83.4% | 2 qtrs — |
| 46 | MONASHEE INVESTMENT MANAGEMENT LLC | 274.9K +274.9K (+100.0%) | 5.90M +5.9M (+100.0%) | 0.31% +0.313 pp | 3.33% +3.327 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 47 | INVESCO LTD. | 270.1K +214.0K (+382.1%) | 5.80M +5.1M (+784.4%) | 0.31% +0.243 pp | 0.00% +0.001 pp | USD19.75 +8.8% | 8 qtrs — |
| 48 | BANK OF NEW YORK MELLON CORP | 263.4K +46.3K (+21.3%) | 5.66M +3.1M (+122.6%) | 0.30% +0.050 pp | 0.00% +0.001 pp | USD12.22 +75.8% | 9 qtrs — |
| 49 | BARCLAYS PLC | 246.1K +140.2K (+132.4%) | 5.29M +3.7M (+241.4%) | 0.28% +0.158 pp | 0.00% +0.001 pp | USD16.88 +27.3% | 9 qtrs — |
| 50 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 237.3K -53.2K (-18.3%) | 5.03M +1.6M (+48.0%) | 0.27% -0.064 pp | 0.00% +0.001 pp | USD11.60 +85.2% | 10 qtrs — |
| 51 | BANK OF AMERICA CORP /DE/ | 202.7K +110.6K (+120.0%) | 4.35M +3.3M (+303.5%) | 0.23% +0.125 pp | 0.00% +0.000 pp | USD15.09 +42.3% | 10 qtrs — |
| 52 | BURKEHILL GLOBAL MANAGEMENT, LP | 200.0K +200.0K (+100.0%) | 4.30M +4.3M (+100.0%) | 0.23% +0.227 pp | 0.28% +0.283 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 53 | NEO IVY CAPITAL MANAGEMENT | 192.6K +192.6K (+100.0%) | 4.14M +4.1M (+100.0%) | 0.22% +0.219 pp | 0.65% +0.654 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 54 | JANE STREET GROUP, LLC | 191.5K +191.5K (+100.0%) | 4.11M +4.1M (+100.0%) | 0.22% +0.218 pp | 0.00% +0.001 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 55 | AMERIPRISE FINANCIAL INC | 190.6K +190.6K (+100.0%) | 4.09M +4.1M (+100.0%) | 0.22% +0.217 pp | 0.00% +0.001 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 56 | SWISS NATIONAL BANK | 185.0K +50.0K (+37.0%) | 3.97M +2.4M (+151.4%) | 0.21% +0.055 pp | 0.00% +0.001 pp | USD16.93 +26.9% | 8 qtrs — |
| 57 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 182.4K +181.7K (+28,530.9%) | 3.92M +3.9M (+55,871.4%) | 0.21% +0.207 pp | 0.00% +0.005 pp | USD21.44 +0.2% | 3 qtrs — |
| 58 | ATOM INVESTORS LP | 175.8K +175.8K (+100.0%) | 3.78M +3.8M (+100.0%) | 0.20% +0.200 pp | 0.30% +0.300 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 59 | GILDER GAGNON HOWE & CO LLC | 174.9K +41.7K (+31.4%) | 3.76M +2.2M (+141.0%) | 0.20% +0.046 pp | 0.04% +0.024 pp | USD14.04 +53.0% | 2 qtrs — |
| 60 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 170.0K +170.0K (+100.0%) | 3.65M +3.7M (+100.0%) | 0.19% +0.193 pp | 0.01% +0.006 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 61 | NUVEEN, LLC | 169.3K +24.0K (+16.5%) | 3.64M +1.9M (+113.7%) | 0.19% +0.026 pp | 0.00% +0.001 pp | USD8.83 +143.3% | 4 qtrs — |
| 62 | SG AMERICAS SECURITIES, LLC | 162.2K +153.4K (+1,749.3%) | 3.48M +3.4M (+3,281.6%) | 0.18% +0.174 pp | 0.00% +0.004 pp | USD20.95 +2.5% | 7 qtrs — |
| 63 | TREXQUANT INVESTMENT LP | 130.8K +130.8K (+100.0%) | 2.81M +2.8M (+100.0%) | 0.15% +0.149 pp | 0.03% +0.025 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 64 | BIRCHVIEW CAPITAL, LP | 130.0K +25.0K (+23.8%) | 2.79M +1.6M (+127.1%) | 0.15% +0.027 pp | 1.63% +0.707 pp | USD12.48 +72.1% | 3 qtrs — |
| 65 | SUMMITTX CAPITAL, L.P. | 127.6K +127.6K (+100.0%) | 2.74M +2.7M (+100.0%) | 0.15% +0.145 pp | 0.08% +0.083 pp | USD21.48 +0.0% | 4 qtrs — |
| 66 | UBS ASSET MANAGEMENT AMERICAS INC | 123.7K +11.5K (+10.2%) | 2.66M +1.3M (+102.1%) | 0.14% +0.012 pp | 0.00% +0.000 pp | USD11.36 +89.1% | 8 qtrs — |
| 67 | RHUMBLINE ADVISERS | 113.6K +5.5K (+5.1%) | 2.44M +1.2M (+92.7%) | 0.13% +0.005 pp | 0.00% +0.001 pp | USD11.19 +92.0% | 7 qtrs — |
| 68 | RAFFERTY ASSET MANAGEMENT, LLC | 113.4K +26.9K (+31.1%) | 2.44M +1.4M (+140.5%) | 0.13% +0.030 pp | 0.01% +0.005 pp | USD13.60 +57.9% | 7 qtrs — |
| 69 | WELLS FARGO & COMPANY/MN | 108.1K +56.7K (+110.3%) | 2.32M +1.7M (+285.7%) | 0.12% +0.064 pp | 0.00% +0.000 pp | USD16.34 +31.5% | 21 qtrs — |
| 70 | NEOS INVESTMENT MANAGEMENT LLC | 103.6K -58.6K (-36.1%) | 2.23M +325.8K (+17.2%) | 0.12% -0.069 pp | 0.01% -0.001 pp | USD9.99 +115.0% | 3 qtrs — |
| 71 | LONGAEVA PARTNERS L.P. | 102.5K +102.5K (+100.0%) | 2.20M +2.2M (+100.0%) | 0.12% +0.117 pp | 0.18% +0.185 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 72 | TEMA ETFS LLC | 102.1K -60.1K (-37.1%) | 2.19M +292.9K (+15.4%) | 0.12% -0.070 pp | 0.17% +0.012 pp | USD9.99 +115.0% | 3 qtrs — |
| 73 | LMR PARTNERS LLP | 100.0K +100.0K (+100.0%) | 2.15M +2.1M (+100.0%) | 0.11% +0.114 pp | 0.00% +0.004 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 74 | AMERICAN CENTURY COMPANIES INC | 98.1K +34.8K (+55.0%) | 2.11M +1.4M (+184.4%) | 0.11% +0.039 pp | 0.00% +0.001 pp | USD15.18 +41.5% | 2 qtrs — |
| 75 | LEGAL & GENERAL GROUP PLC | 95.0K +13.9K (+17.1%) | 2.04M +1.1M (+114.8%) | 0.11% +0.015 pp | 0.00% +0.000 pp | USD15.47 +38.8% | 8 qtrs — |
| 76 | ALLIANCEBERNSTEIN L.P. | 93.0K +37.7K (+68.3%) | 2.00M +1.4M (+208.7%) | 0.11% +0.042 pp | 0.00% +0.000 pp | USD15.75 +36.4% | 7 qtrs — |
| 77 | NISA INVESTMENT ADVISORS, LLC | 80.2K -198.0 (-0.2%) | 1.72M +781.5K (+83.0%) | 0.09% -0.001 pp | 0.01% +0.002 pp | USD11.61 +85.0% | 6 qtrs — |
| 78 | DEUTSCHE BANK AG\ | 76.2K +15.3K (+25.1%) | 1.64M +923.9K (+129.5%) | 0.09% +0.017 pp | 0.00% +0.000 pp | USD12.96 +65.7% | 8 qtrs — |
| 79 | MAVEN SECURITIES LTD | 75.0K +75.0K (+100.0%) | 1.61M +1.6M (+100.0%) | 0.09% +0.085 pp | 0.04% +0.036 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 80 | VERITION FUND MANAGEMENT LLC | 72.9K +72.9K (+100.0%) | 1.57M +1.6M (+100.0%) | 0.08% +0.083 pp | 0.01% +0.006 pp | USD21.48 +0.0% | 5 qtrs — |
| 81 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 67.0K +1.2K (+1.8%) | 1.44M +668.4K (+86.7%) | 0.08% +0.001 pp | 0.00% +0.001 pp | USD16.77 +28.1% | 8 qtrs — |
| 82 | NOMURA HOLDINGS INC | 64.4K +64.4K (+100.0%) | 1.38M +1.4M (+100.0%) | 0.07% +0.073 pp | 0.00% +0.002 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 83 | FREESTONE CAPITAL HOLDINGS, LLC | 61.5K -78.0 (-0.1%) | 1.32M +600.4K (+83.2%) | 0.07% -0.001 pp | 0.04% +0.017 pp | USD6.73 +219.2% | 4 qtrs — |
| 84 | DARK FOREST CAPITAL MANAGEMENT LP | 57.2K +57.2K (+100.0%) | 1.23M +1.2M (+100.0%) | 0.07% +0.065 pp | 0.06% +0.056 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 85 | ERSTE ASSET MANAGEMENT GMBH | 52.0K +52.0K (+100.0%) | 1.12M +1.1M (+100.0%) | 0.06% +0.059 pp | 0.01% +0.009 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 86 | METLIFE INVESTMENT MANAGEMENT, LLC | 52.0K +9.6K (+22.7%) | 1.12M +621.1K (+125.1%) | 0.06% +0.010 pp | 0.01% +0.003 pp | USD13.83 +55.3% | 7 qtrs — |
| 87 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 50.1K +9.8K (+24.4%) | 1.07M +604.7K (+128.6%) | 0.06% +0.011 pp | 0.00% +0.001 pp | USD13.79 +55.8% | 7 qtrs — |
| 88 | QUEST PARTNERS LLC | 49.0K +3.9K (+8.7%) | 1.05M +524.2K (+99.3%) | 0.06% +0.004 pp | 0.06% +0.024 pp | USD8.43 +154.8% | 7 qtrs — |
| 89 | BALDWIN INVESTMENT MANAGEMENT, LLC | 47.2K +21.8K (+85.7%) | 1.01M +715.8K (+240.7%) | 0.05% +0.024 pp | 0.11% +0.080 pp | USD12.97 +65.6% | 20 qtrs — |
| 90 | RAYMOND JAMES FINANCIAL INC | 46.6K +36.3K (+352.1%) | 1.00M +879.7K (+729.3%) | 0.05% +0.041 pp | 0.00% +0.000 pp | USD19.23 +11.7% | 5 qtrs — |
| 91 | MAGNUS FINANCIAL GROUP LLC | 45.8K -7.8K (-14.5%) | 982.9K +356.0K (+56.8%) | 0.05% -0.010 pp | 0.08% +0.026 pp | USD18.37 +16.9% | 20 qtrs — |
| 92 | STATE OF WISCONSIN INVESTMENT BOARD | 45.7K +45.7K (+100.0%) | 982.6K +982.6K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.002 pp | USD21.48 +0.0% | 1 qtrs NEW |
| 93 | LOS ANGELES CAPITAL MANAGEMENT LLC | 59.4K -27.7K (-31.8%) | 949.5K -70.5K (-6.9%) | 0.07% -0.033 pp | 0.00% 0.000 pp | USD11.09 +93.7% | 5 qtrs — |
| 94 | LIDO ADVISORS, LLC | 59.1K +— (+0.0%) | 691.5K +— (+0.0%) | 0.07% -0.001 pp | 0.00% 0.000 pp | USD6.99 +207.3% | 4 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.40
Bearish
Ratio by volume
0.49
Bearish
Buys
2
Sells
5
Shares acquired
71.6K
Shares disposed
146.0K
Cash buys
—
Cash sales
3.00
Net activity
-74,438
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Rosett Max | Officer | M-Exempt | A | Common Stock | 39,713 | 1.35 | 53.6K | 119,037 | D | ↗ |
| 2026-04-02 | Higgins Jack | Officer | S-Sale | D | Common Stock | 9,438 | 21.64 | 204.2K | 22,000 | D | ↗ |
| 2026-03-30 | Higgins Jack | Officer | G-Gift | D | Common Stock | 6,291 | 0.00 | — | 31,438 | D | ↗ |
| 2026-03-27 | SIEGALL CLAY B | Director / Officer | P-Purchase | A | Common Stock | 25,450 | 19.67 | 500.6K | 690,704 | D | ↗ |
| 2026-03-23 | WAGENHEIM PHILIP | Director | S-Sale | D | Common Stock | 28,200 | 20.65 | 582.3K | 341,147 | D | ↗ |
| 2026-03-20 | WAGENHEIM PHILIP | Director | S-Sale | D | Common Stock | 36,800 | 20.47 | 753.3K | 369,347 | D | ↗ |
| 2026-03-11 | BIENAIME JEAN JACQUES | Director | P-Purchase | A | Common Stock | 1,000 | 21.55 | 21.6K | 38,415 | D | ↗ |
| 2026-03-10 | BIENAIME JEAN JACQUES | Director | P-Purchase | A | Common Stock | 1,000 | 22.12 | 22.1K | 37,415 | D | ↗ |
| 2025-12-30 | SIEGALL CLAY B | Director / Officer | P-Purchase | A | Common Stock | 4,729 | 21.15 | 100.0K | 665,254 | D | ↗ |
| 2025-12-22 | Barchas Isaac | Director | S-Sale | D | Common Stock | 371,949 | 21.72 | 8.08M | 2,042,432 | I | ↗ |
| 2025-12-19 | Tsai Philip | Officer | P-Purchase | A | Common Stock | 10,000 | 20.49 | 204.9K | 43,300 | D | ↗ |
| 2025-12-19 | SIEGALL CLAY B | Director / Officer | P-Purchase | A | Common Stock | 7,278 | 20.48 | 149.1K | 860,525 | D | ↗ |
| 2025-12-19 | Higgins Jack | Officer | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 39,729 | D | ↗ |
| 2025-12-18 | SIEGALL CLAY B | Director / Officer | P-Purchase | A | Common Stock | 46,511 | 21.50 | 1,000.0K | 853,247 | D | ↗ |
| 2025-09-10 | Higgins Jack | Officer | M-Exempt | D | Employee Stock option (right to buy) | 22,000 | 1.35 | 29.7K | 151,840 | D | ↗ |
| 2025-07-29 | Tsai Philip | Officer | A-Award | A | Employee Stock Option (right to buy) | 190,000 | 10.60 | 2.01M | 190,000 | D | ↗ |
| 2025-07-29 | Stoneman Sandra G. | Officer | A-Award | A | Employee Stock Option (right to buy) | 190,000 | 10.60 | 2.01M | 190,000 | D | ↗ |
| 2025-07-29 | SIEGALL CLAY B | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 800,000 | 10.60 | 8.48M | 800,000 | D | ↗ |
| 2025-07-29 | Rosett Max | Officer | A-Award | A | Employee Stock Option (right to buy) | 207,000 | 10.60 | 2.19M | 207,000 | D | ↗ |
| 2025-07-29 | Lechleider Robert | Officer | A-Award | A | Employee Stock Option (right to buy) | 242,000 | 10.60 | 2.57M | 242,000 | D | ↗ |
| 2025-07-29 | Horn Kinney | Officer | A-Award | A | Employee Stock Option (right to buy) | 161,000 | 10.60 | 1.71M | 161,000 | D | ↗ |
| 2025-07-29 | Higgins Jack | Officer | A-Award | A | Employee Stock Option (right to buy) | 196,000 | 10.60 | 2.08M | 196,000 | D | ↗ |
| 2025-06-10 | WAGENHEIM PHILIP | Director | A-Award | A | Director Stock Option (right to buy) | 18,864 | 9.57 | 180.5K | 18,864 | D | ↗ |
| 2025-06-10 | SWAIN SANDRA M | Director | A-Award | A | Director Stock Option (right to buy) | 18,864 | 9.57 | 180.5K | 18,864 | D | ↗ |
| 2025-06-10 | SCHAFER CAROL | Director | A-Award | A | Director Stock Option (right to buy) | 18,864 | 9.57 | 180.5K | 18,864 | D | ↗ |
| 2025-06-10 | Boylan James P | Director | A-Award | A | Director Stock Option (right to buy) | 18,864 | 9.57 | 180.5K | 18,864 | D | ↗ |
| 2025-06-10 | Barchas Isaac | Director | A-Award | A | Director Stock Option (right to buy) | 18,864 | 9.57 | 180.5K | 18,864 | D | ↗ |
| 2025-06-10 | BIENAIME JEAN JACQUES | Director | A-Award | A | Director Stock Option (right to buy) | 18,864 | 9.57 | 180.5K | 18,864 | D | ↗ |
| 2025-06-03 | BIENAIME JEAN JACQUES | Director | P-Purchase | A | Common Stock | 5,000 | 9.38 | 46.9K | 36,415 | D | ↗ |
| 2025-03-27 | Higgins Jack | Officer | M-Exempt | D | Employee Stock option (right to buy) | 5,200 | 1.35 | 7.0K | 173,840 | D | ↗ |
| 2025-03-26 | SIEGALL CLAY B | Director / Officer | P-Purchase | A | Common Stock | 137,100 | 7.29 | 999.5K | 806,736 | D | ↗ |
| 2025-03-25 | BIENAIME JEAN JACQUES | Director | P-Purchase | A | Common Stock | 7,800 | 7.78 | 60.7K | 31,415 | D | ↗ |
| 2025-03-24 | Tsai Philip | Officer | P-Purchase | A | Common Stock | 12,300 | 8.42 | 103.6K | 33,300 | D | ↗ |
| 2025-03-24 | BIENAIME JEAN JACQUES | Director | P-Purchase | A | Common Stock | 7,000 | 8.21 | 57.5K | 23,615 | D | ↗ |
| 2025-01-31 | SIEGALL CLAY B | Director / Officer | P-Purchase | A | Common Stock | 150,000 | 7.75 | 1.16M | 669,636 | D | ↗ |
| 2024-11-22 | SIEGALL CLAY B | Director / Officer | P-Purchase | A | Common Stock | 33,943 | 9.78 | 331.9K | 519,636 | D | ↗ |
| 2024-11-21 | Tsai Philip | Officer | P-Purchase | A | Common Stock | 21,000 | 9.43 | 198.0K | 21,000 | D | ↗ |
| 2024-11-21 | SIEGALL CLAY B | Director / Officer | P-Purchase | A | Common Stock | 66,057 | 9.54 | 630.3K | 485,693 | D | ↗ |
| 2024-11-21 | Lechleider Robert | Officer | P-Purchase | A | Common Stock | 15,805 | 9.48 | 149.8K | 15,805 | D | ↗ |
| 2024-09-19 | Rosett Max | Officer | S-Sale | D | Common Stock | 14,380 | 16.01 | 230.2K | 47,476 | D | ↗ |
| 2024-08-19 | Higgins Jack | Officer | G-Gift | D | Common Stock | 2,471 | 0.00 | — | 13,529 | — | ↗ |
| 2024-08-16 | BIENAIME JEAN JACQUES | Director | P-Purchase | A | Common Stock | 7,000 | 13.94 | 97.6K | 16,615 | — | ↗ |
| 2024-08-15 | Higgins Jack | Officer | M-Exempt | D | Stock option (right to buy) | 19,524 | 1.35 | 26.4K | 179,040 | — | ↗ |
| 2024-08-09 | Turner Bruce | Officer | A-Award | A | Stock option (right to buy) | 110,000 | 12.92 | 1.42M | 110,000 | — | ↗ |
| 2024-08-09 | Stoneman Sandra G. | Officer | A-Award | A | Stock option (right to buy) | 210,000 | 12.92 | 2.71M | 210,000 | — | ↗ |
| 2024-08-09 | SIEGALL CLAY B | Director / Officer | A-Award | A | Stock option (right to buy) | 800,000 | 12.92 | 10.34M | 800,000 | — | ↗ |
| 2024-08-09 | Rosett Max | Officer | A-Award | A | Stock option (right to buy) | 190,000 | 12.92 | 2.45M | 190,000 | — | ↗ |
| 2024-08-09 | Lechleider Robert | Officer | A-Award | A | Stock option (right to buy) | 200,000 | 12.92 | 2.58M | 200,000 | — | ↗ |
| 2024-08-09 | Horn Kinney | Officer | A-Award | A | Stock option (right to buy) | 130,000 | 12.92 | 1.68M | 130,000 | — | ↗ |
| 2024-08-09 | Higgins Jack | Officer | A-Award | A | Stock option (right to buy) | 190,000 | 12.92 | 2.45M | 190,000 | — | ↗ |
| 2024-06-17 | Tsai Philip | Officer | A-Award | A | Stock option (right to buy) | 250,000 | 13.15 | 3.29M | 250,000 | — | ↗ |
| 2024-06-13 | WAGENHEIM PHILIP | Director | A-Award | A | Stock option (right to buy) | 11,333 | 16.04 | 181.8K | 11,333 | — | ↗ |
| 2024-06-13 | SWAIN SANDRA M | Director | A-Award | A | Stock option (right to buy) | 11,333 | 16.04 | 181.8K | 11,333 | — | ↗ |
| 2024-06-13 | SCHAFER CAROL | Director | A-Award | A | Stock option (right to buy) | 11,333 | 16.04 | 181.8K | 11,333 | — | ↗ |
| 2024-06-13 | Boylan James P | Director | A-Award | A | Stock option (right to buy) | 11,333 | 16.04 | 181.8K | 11,333 | — | ↗ |
| 2024-06-13 | Barchas Isaac | Director | A-Award | A | Stock option (right to buy) | 11,333 | 16.04 | 181.8K | 11,333 | — | ↗ |
| 2024-06-13 | BIENAIME JEAN JACQUES | Director | A-Award | A | Stock option (right to buy) | 11,333 | 16.04 | 181.8K | 11,333 | — | ↗ |
| 2024-05-21 | SIEGALL CLAY B | Director / Officer | P-Purchase | A | Common Stock | 20,434 | 13.78 | 281.5K | 419,636 | — | ↗ |
| 2024-05-21 | BIENAIME JEAN JACQUES | Director | P-Purchase | A | Common Stock | 2,000 | 13.57 | 27.1K | 9,615 | — | ↗ |
| 2024-05-20 | SIEGALL CLAY B | Director / Officer | P-Purchase | A | Common Stock | 79,566 | 13.91 | 1.11M | 399,202 | — | ↗ |
| 2024-05-16 | Rosett Max | Officer | A-Award | A | Stock option (right to buy) | 30,000 | 14.40 | 432.0K | 30,000 | — | ↗ |
| 2024-04-25 | SWAIN SANDRA M | Director | A-Award | A | Stock option (right to buy) | 25,737 | 14.26 | 367.0K | 25,737 | — | ↗ |
| 2024-02-20 | Horn Kinney | Officer | A-Award | A | Stock option (right to buy) | 300,000 | 23.00 | 6.90M | 300,000 | — | ↗ |
| 2024-02-12 | Horn Kinney | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-31 | Stoneman Sandra G. | Officer | A-Award | A | Stock option (right to buy) | 200,000 | 16.57 | 3.31M | 200,000 | — | ↗ |
| 2024-01-31 | Rosett Max | Officer | A-Award | A | Stock option (right to buy) | 175,000 | 16.57 | 2.90M | 175,000 | — | ↗ |
| 2024-01-02 | SCHAFER CAROL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-02 | Lapetina Bob | Officer | — | D | Common Stock | 0 | 0.00 | — | 12,047 | — | ↗ |
| 2023-12-13 | Roberts Phil Noland | Officer | A-Award | A | Stock option (right to buy) | 275,000 | 7.34 | 2.02M | 275,000 | — | ↗ |
| 2023-12-08 | Roberts Phil Noland | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-01 | Higgins Jack | Officer | A-Award | A | Stock option (right to buy) | 200,000 | 7.80 | 1.56M | 200,000 | — | ↗ |
| 2023-11-07 | BIENAIME JEAN JACQUES | Director | A-Award | A | Stock option (right to buy) | 40,696 | 8.91 | 362.6K | 40,696 | — | ↗ |
| 2023-10-27 | Lechleider Robert | Officer | A-Award | A | Stock option (right to buy) | 400,000 | 8.73 | 3.49M | 400,000 | — | ↗ |
| 2023-10-27 | Boylan James P | Director | A-Award | A | Stock option (right to buy) | 41,538 | 8.73 | 362.6K | 41,538 | — | ↗ |
| 2023-10-27 | Barchas Isaac | Director | A-Award | A | Stock option (right to buy) | 41,538 | 8.73 | 362.6K | 41,538 | — | ↗ |
| 2023-10-16 | Lechleider Robert | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-02 | Turner Bruce | Officer | P-Purchase | A | Common Stock | 42,300 | 5.91 | 250.0K | 42,300 | — | ↗ |
| 2023-10-02 | SIEGALL CLAY B | Director / Officer | — | D | Stock Option (Right to Buy) | 1,191,399 | 1.35 | 1.61M | 0 | — | ↗ |
| 2023-10-02 | Rosett Max | Officer | — | D | Stock Option (Right to Buy) | 39,713 | 1.35 | 53.6K | 0 | — | ↗ |
| 2023-10-02 | RAPP MICHAEL | Director | A-Award | A | Common Stock | 253,806 | 5.91 | 1.50M | 1,071,172 | — | ↗ |
| 2023-10-02 | PRENDERGAST FRANKLYN G | Director | A-Award | A | Stock Option (Right to Buy) | 137,725 | 1.35 | 185.9K | 137,725 | — | ↗ |
| 2023-10-02 | Higgins Jack | Officer | — | D | Stock Option (Right to Buy) | 198,564 | 1.35 | 268.1K | 0 | — | ↗ |
| 2023-10-02 | Boylan James P | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-02 | Barchas Isaac | Director | — | D | Stock Option (Right to Buy) | 76,885 | 1.35 | 103.8K | 0 | — | ↗ |
| 2023-06-08 | WAGENHEIM PHILIP | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 4.84 | 31.5K | 6,500 | — | ↗ |
| 2023-06-08 | Stoneman Sandra G. | Officer | A-Award | A | Stock Option (Right to Buy) | 56,000 | 4.84 | 271.0K | 56,000 | — | ↗ |
| 2023-06-08 | Sarma Purnanand D | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 166,500 | 4.84 | 805.9K | 166,500 | — | ↗ |
| 2023-06-08 | Roche Corleen M. | Officer | A-Award | A | Stock Option (Right to Buy) | 58,000 | 4.84 | 280.7K | 58,000 | — | ↗ |
| 2023-06-08 | ROBINSON MATTHEW K | Officer | A-Award | A | Stock Option (Right to Buy) | 58,000 | 4.84 | 280.7K | 58,000 | — | ↗ |
| 2023-06-08 | RAPP MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 4.84 | 31.5K | 6,500 | — | ↗ |
| 2023-06-08 | PRENDERGAST FRANKLYN G | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 4.84 | 31.5K | 6,500 | — | ↗ |
| 2023-06-08 | Lefenfeld Michael | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 4.84 | 31.5K | 6,500 | — | ↗ |
| 2023-06-08 | LAMATTINA JOHN L | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 4.84 | 31.5K | 6,500 | — | ↗ |
| 2023-06-08 | Giesing Dennis H | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 4.84 | 242.0K | 50,000 | — | ↗ |
| 2023-06-08 | BARON RICHARD A | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 4.84 | 31.5K | 6,500 | — | ↗ |
| 2023-01-15 | WAGENHEIM PHILIP | Director | A-Award | A | Common Stock | 8,750 | 4.00 | 35.0K | 406,147 | — | ↗ |
| 2023-01-15 | RAPP MICHAEL | Director | A-Award | A | Common Stock | 17,500 | 4.00 | 70.0K | 817,366 | — | ↗ |
| 2023-01-15 | Lefenfeld Michael | Director | A-Award | A | Common Stock | 13,875 | 4.00 | 55.5K | 40,747 | — | ↗ |
| 2023-01-15 | LAMATTINA JOHN L | Director | A-Award | A | Common Stock | 15,125 | 4.00 | 60.5K | 66,953 | — | ↗ |
| 2022-06-16 | WAGENHEIM PHILIP | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2022-06-16 | Stoneman Sandra G. | Officer | A-Award | A | Stock Option (Right to Buy) | 43,000 | 3.42 | 147.1K | 43,000 | — | ↗ |
| 2022-06-16 | Sarma Purnanand D | Officer | A-Award | A | Stock Option (Right to Buy) | 121,000 | 0.00 | — | 121,000 | — | ↗ |
| 2022-06-16 | Roche Corleen M. | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 0.00 | — | 70,000 | — | ↗ |
| 2022-06-16 | ROBINSON MATTHEW K | Officer | A-Award | A | Stock Option (Right to Buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-06-16 | RAPP MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2022-06-16 | PRENDERGAST FRANKLYN G | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2022-06-16 | Lefenfeld Michael | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2022-06-16 | LAMATTINA JOHN L | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 2.62 | 17.0K | 6,500 | — | ↗ |
| 2022-06-16 | Giesing Dennis H | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-06-16 | BARON RICHARD A | Director | A-Award | A | Stock Option (Right to Buy) | 6,500 | 0.00 | — | 6,500 | — | ↗ |
| 2022-06-15 | ROBINSON MATTHEW K | Officer | — | D | Stock Option (Right to Buy) | 5,000 | 0.06 | 300.00 | 0 | — | ↗ |
| 2021-09-13 | RAPP MICHAEL | Director | P-Purchase | A | Common Stock | 25,962 | 19.96 | 518.2K | 208,742 | — | ↗ |
| 2021-09-10 | RAPP MICHAEL | Director | P-Purchase | A | Common Stock | 15,500 | 17.85 | 276.7K | 182,780 | — | ↗ |
| 2021-09-09 | RAPP MICHAEL | Director | P-Purchase | A | Common Stock | 22,280 | 18.46 | 411.3K | 167,280 | — | ↗ |
| 2021-08-18 | BARON RICHARD A | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,343 | 11.38 | 26.7K | 5,157 | — | ↗ |
| 2021-06-16 | PRENDERGAST FRANKLYN G | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 16.96 | 127.2K | 7,500 | — | ↗ |
| 2021-05-28 | Widlitz Michael | Director | A-Award | A | Stock Option (Right to Buy) | 3,750 | 20.92 | 78.5K | 3,750 | — | ↗ |
| 2021-05-28 | WAGENHEIM PHILIP | Director | A-Award | A | Stock Option (Right to Buy) | 3,750 | 20.92 | 78.5K | 3,750 | — | ↗ |
| 2021-05-28 | Stoneman Sandra G. | Officer | A-Award | A | Stock Option (Right to Buy) | 16,609 | 20.92 | 347.5K | 16,609 | — | ↗ |
| 2021-05-28 | Sarma Purnanand D | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 93,354 | 20.92 | 1.95M | 93,354 | — | ↗ |
| 2021-05-28 | Roche Corleen M. | Officer | A-Award | A | Stock Option (Right to Buy) | 16,609 | 20.92 | 347.5K | 16,609 | — | ↗ |
| 2021-05-28 | RAPP MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 3,750 | 20.92 | 78.5K | 3,750 | — | ↗ |
| 2021-05-28 | Lefenfeld Michael | Director | A-Award | A | Stock Option (Right to Buy) | 3,750 | 20.92 | 78.5K | 3,750 | — | ↗ |
| 2021-05-28 | LAMATTINA JOHN L | Director | A-Award | A | Stock Option (Right to Buy) | 3,750 | 20.92 | 78.5K | 3,750 | — | ↗ |
| 2021-05-28 | Giesing Dennis H | Officer | A-Award | A | Stock Option (Right to Buy) | 16,609 | 20.92 | 347.5K | 16,609 | — | ↗ |
| 2021-05-28 | BARON RICHARD A | Director | A-Award | A | Stock Option (Right to Buy) | 3,750 | 20.92 | 78.5K | 3,750 | — | ↗ |
| 2021-05-26 | RAPP MICHAEL | Director | P-Purchase | A | Common Stock | 2,300 | 18.94 | 43.6K | 136,830 | — | ↗ |
| 2021-05-26 | Lefenfeld Michael | Director | P-Purchase | A | Common Stock | 1,335 | 19.03 | 25.4K | 26,872 | — | ↗ |
| 2021-05-25 | Sarma Purnanand D | Director / Officer | P-Purchase | A | Common Stock | 10,500 | 18.41 | 193.3K | 10,500 | — | ↗ |
| 2021-05-25 | RAPP MICHAEL | Director | P-Purchase | A | Common Stock | 19,303 | 18.32 | 353.6K | 134,530 | — | ↗ |
| 2021-05-25 | Lefenfeld Michael | Director | P-Purchase | A | Common Stock | 2,715 | 18.44 | 50.1K | 25,537 | — | ↗ |
| 2021-05-24 | WAGENHEIM PHILIP | Director | P-Purchase | A | Common Stock | 13,500 | 18.35 | 247.7K | 397,397 | — | ↗ |
| 2021-05-24 | RAPP MICHAEL | Director | P-Purchase | A | Common Stock | 31,895 | 18.38 | 586.2K | 115,227 | — | ↗ |
| 2021-05-24 | Lefenfeld Michael | Director | P-Purchase | A | Common Stock | 600 | 17.80 | 10.7K | 22,822 | — | ↗ |
| 2021-05-24 | LAMATTINA JOHN L | Director | P-Purchase | A | Common Stock | 338 | 18.44 | 6.2K | 46,726 | — | ↗ |
| 2021-04-19 | Roche Corleen M. | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 27.53 | 3.44M | 125,000 | — | ↗ |
| 2021-03-25 | Giesing Dennis H | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 31.83 | 3.98M | 125,000 | — | ↗ |
| 2021-03-23 | Giesing Dennis H | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-04 | Marcou Diane M | Officer | — | D | Stock Option (right to buy) | 8,333 | 2.40 | 20.0K | 0 | — | ↗ |
| 2020-11-03 | Widlitz Michael | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 11.38 | 85.4K | 7,500 | — | ↗ |
| 2020-11-03 | WAGENHEIM PHILIP | Director | A-Award | A | Stock Option (Right to Buy)(1) | 7,500 | 11.38 | 85.4K | 7,500 | — | ↗ |
| 2020-11-03 | Stoneman Sandra G. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 148,837 | 11.38 | 1.69M | 148,837 | — | ↗ |
| 2020-11-03 | RAPP MICHAEL | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 7,500 | 11.38 | 85.4K | 7,500 | — | ↗ |
| 2020-11-03 | Lefenfeld Michael | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 11.38 | 85.4K | 7,500 | — | ↗ |
| 2020-11-03 | LAMATTINA JOHN L | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 11.38 | 85.4K | 7,500 | — | ↗ |
| 2020-11-03 | BARON RICHARD A | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 11.38 | 85.4K | 7,500 | — | ↗ |
| 2020-10-26 | Stoneman Sandra G. | Officer | — | D | Common Stock | 0 | 0.00 | — | 5,555 | — | ↗ |
| 2020-10-06 | Widlitz Michael | Director | C-Conversion | D | Series A Convertible Preferred Stock | 51,315 | 0.00 | — | 0 | — | ↗ |
| 2020-10-06 | RAPP MICHAEL | Director | C-Conversion | D | Series A Convertible Preferred Stock | 555,554 | 0.00 | — | 0 | — | ↗ |
| 2020-10-06 | MORRIS I WISTAR III | 10% Owner | C-Conversion | D | Warrant (right to buy) | 111,111 | 9.00 | 1,000.0K | 0 | — | ↗ |
| 2020-10-06 | Lefenfeld Michael | Director | C-Conversion | D | Series A Convertible Preferred Stock | 22,222 | 0.00 | — | 0 | — | ↗ |
| 2020-10-06 | LAMATTINA JOHN L | Director | C-Conversion | D | Series A Convertible Preferred Stock | 46,388 | 0.00 | — | 0 | — | ↗ |
| 2020-10-01 | Widlitz Michael | Director | — | D | Series A Convertible Preferred Stock | 51,315 | 0.00 | — | 0 | — | ↗ |
| 2020-10-01 | WAGENHEIM PHILIP | Director | — | I | Common Stock | 0 | 0.00 | — | 166,666 | — | ↗ |
| 2020-10-01 | Sarma Purnanand D | Director / Officer | — | D | Employee Stock Option (right to buy) | 51,205 | 2.40 | 122.9K | 0 | — | ↗ |
| 2020-10-01 | RAPP MICHAEL | Director | — | D | Warrant (right to buy) | 166,666 | 9.00 | 1.50M | 0 | — | ↗ |
| 2020-10-01 | Morin Michael | Officer | — | D | Employee Stock Option (right to buy) | 60,426 | 0.54 | 32.6K | 0 | — | ↗ |
| 2020-10-01 | MORRIS I WISTAR III | 10% Owner | — | D | Warrant (right to buy) | 111,111 | 9.00 | 1,000.0K | 0 | — | ↗ |
| 2020-10-01 | Lefenfeld Michael | Director | — | D | Series A Convertible Preferred Stock | 22,222 | 0.00 | — | 0 | — | ↗ |
| 2020-10-01 | LAMATTINA JOHN L | Director | — | I | Series A Convertible Preferred Stock | 46,388 | 0.00 | — | 0 | — | ↗ |
| 2020-10-01 | Fitzgerald Richard F | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-01 | BARON RICHARD A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-12.1K
Shares Outstanding
87.86M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Clay Siegall, Ph.D. President, Chief Executive Officer and Chairman of the Board | 735.0K | — | — | 6.27M | 661.5K | 13.3K | 7.68M | 81.65% | ↗ |
| 2 | 2025 | Max Rosett Chief Financial Officer | 472.5K | — | — | 1.62M | 278.8K | 411.2K | 2.79M | 58.27% | ↗ |
| 3 | 2025 | Robert Lechleider, M.D. Chief Medical Officer | 530.3K | — | — | 1.90M | 307.6K | 12.2K | 2.75M | 69.06% | ↗ |
| 4 | 2024 | Clay B. Siegall, Ph.D. President, Chief Executive Officer and Chairman of the Board | 700.0K | — | — | 7.99M | 525.0K | 10.4K | 9.23M | 86.61% | ↗ |
| 5 | 2024 | Clay Siegall, Ph.D. President, Chief Executive Officer and Chairman of the Board | 700.0K | — | — | 7.99M | 525.0K | 10.4K | 9.23M | 86.61% | ↗ |
| 6 | 2024 | Kinney Horn Chief Business Officer | 382.8K | 25.0K | — | 6.39M | 180.7K | 10.4K | 6.99M | 91.43% | ↗ |
| 7 | 2024 | Sandra G. Stoneman Chief Legal Officer | 470.0K | — | — | 4.53M | 235.0K | 10.4K | 5.25M | 86.37% | ↗ |
| 8 | 2023 | Clay B. Siegall, Ph.D. President, Chief Executive Officer and Chairman of the Board | 162.5K | — | — | 14.22M | 483.6K | 4.9K | 14.87M | 95.62% | ↗ |
| 9 | 2023 | Bob Lechleider, M.D. Chief Medical Officer | 101.0K | 50.0K | — | 2.71M | 58.3K | — | 2.92M | 92.82% | ↗ |
| 10 | 2023 | Jack Higgins, Ph.D. Chief Scientific Officer | 107.9K | 250.0K | — | 1.21M | 266.8K | 3.2K | 1.84M | 65.89% | ↗ |
| 11 | 2023 | Purnanand D. Sarma, Ph.D. Former Chief Executive Officer | 440.8K | 210.6K | — | 38.2K | — | 741.2K | 1.44M | 2.66% | ↗ |
| 12 | 2022 | Purnanand D. Sarma, Ph.D. Former Chief Executive Officer | 540.0K | — | — | 221.3K | 216.0K | 13.0K | 990.3K | 22.35% | ↗ |
| 13 | 2022 | Purnanand D. Sarma, Ph.D. President, Chief Executive Officer and Director | 540.0K | — | — | 221.3K | 216.0K | 13.0K | 990.3K | 22.35% | ↗ |
| 14 | 2022 | Corleen M. Roche Chief Financial Officer | 412.0K | 40.0K | — | 127.2K | 164.8K | 16.3K | 760.3K | 16.73% | ↗ |
| 15 | 2022 | Dennis H. Giesing, Ph.D. Chief Development Officer | 385.0K | 100.0K | — | 108.9K | 115.5K | 6.2K | 715.6K | 15.22% | ↗ |
| 16 | 2021 | Dennis H. Giesing, Ph.D. Chief Development Officer | 307.0K | 50.0K | — | 3.06M | 84.3K | 3.0K | 3.50M | 87.31% | ↗ |
| 17 | 2021 | Corleen M. Roche Chief Financial Officer | 282.1K | 50.0K | — | 2.67M | 89.8K | 3.9K | 3.10M | 86.25% | ↗ |
| 18 | 2021 | Purnanand D. Sarma, Ph.D. President, Chief Executive Officer and Director | 540.0K | — | — | 1.37M | 189.0K | 11.9K | 2.11M | 64.92% | ↗ |
| 19 | 2020 | Purnanand D. Sarma, Ph.D. President, Chief Executive Officer and Director | 435.0K | — | — | 1.04M | 211.6K | 10.9K | 1.70M | 61.21% | ↗ |
| 20 | 2020 | Purnanand D. Sarma, Ph.D. President, Chief Executive Officer and Director | 435.0K | — | — | 1.04M | 211.6K | 10.9K | 1.70M | 61.21% | ↗ |
| 21 | 2020 | Sandra G. Stoneman Chief Legal Officer and General Counsel | 71.6K | 15.0K | — | 1.20M | 30.6K | 366.00 | 1.31M | 91.06% | ↗ |
| 22 | 2020 | Michael J. Morin, Ph.D. Chief Scientific Officer | 249.4K | — | — | 559.7K | 108.2K | 19.5K | 936.8K | 59.74% | ↗ |
| 23 | 2019 | Michael J. Morin, Ph.D. Chief Scientific Officer | 220.0K | — | — | — | 110.0K | 33.8K | 363.8K | 0.00% | ↗ |
| 24 | 2019 | Purnanand D. Sarma, Ph.D. President, Chief Executive Officer and Director | 233.3K | — | — | — | 81.7K | 24.9K | 339.9K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Clay Siegall | Chairman, President & Chief Executive Officer | 1M | — |
| Max Rosett | Chief Financial Officer | 1M | male |
| Jack Higgins | Chief Scientific Officer | 956.3K | — |
| Robert J. Lechleider | Chief Medical Officer | 850.1K | — |
| Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary | 715.4K | female |
| Kinney Horn | Chief Business Officer | 598.9K | male |
| Philip Tsai | Chief Technical Officer | — | — |
| Roee Shahar | Executive Vice President of Commercial | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMNM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
